Oxeia Biopharmaceuticals, Inc.
Regulation Crowdfunding offering on Dealmaker
$6,771
of $2.64M goal
0.3% funded
About the offering
Oxeia Biopharmaceuticals is a clinical-stage biopharmaceutical company that is developing OXE-103, a ghrelin-based drug candidate intended to be the first approved treatment for concussion, in the United States.
FAQ
How much has Oxeia Biopharmaceuticals, Inc. raised?
Oxeia Biopharmaceuticals, Inc. has raised $6,771 of a $2.64M goal.
Where is Oxeia Biopharmaceuticals, Inc.'s campaign live?
The offering is live on Dealmaker, an SEC-registered Reg CF intermediary.
What are the terms of Oxeia Biopharmaceuticals, Inc.'s raise?
Preferred Stock, $50M cap, $0.79/share.
When does Oxeia Biopharmaceuticals, Inc.'s offering close?
The stated close date is Apr 25, 2027.
